MarketPulse

cash runway

9 articles
BenzingaBenzinga··Globe Newswire

Reviva Pharmaceuticals Closes $10M Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.
RVPHwarrantspublic offering
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 700% as Top Fund Trims Position Yet Doubles Down

Cormorant Asset Management sold $PRAX shares for $9.3M in Q4, yet position surged $227M in value. Stock remains fund's largest holding at $280M.
EYPTPRAXABVXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Seres Therapeutics, Inc.

Seres Therapeutics Swings to $5.7M Profit on Nestlé VOWST Sale, Eyes 2026 Clinical Data

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.
MCRBclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lyell Immunopharma Secures $50M Funding Tranche on Clinical Progress

Lyell Immunopharma closes $50M funding tranche, advances ronde-cel in pivotal lymphoma trial, appoints new CFO with extended cash runway through Q2 2027.
LYELCAR T-cell therapycash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boundless Bio Extends Cash Runway to Mid-2028 Amid BBI-940 Clinical Expansion

Boundless Bio reported $107.6M cash, narrowed 2025 net losses to $58.2M, and is advancing lead breast cancer candidate BBI-940 through Phase 2 trials.
BOLDbreast cancercash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical